PDF(Pubmed)
Abstract：
BACKGROUND: SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID).
OBJECTIVE: The aim is to retrospectively analyze a cohort of hospitalized patients with first-wave (February 2020-June 2020) SARS-CoV-2 infection and persisting unclear cholangiopathy to determine the incidence of SSC-COVID and its risk factors.
RESULTS: A total of 249 patients were hospitalized at the university hospital in Tübingen, Germany, with SARS-CoV-2 infection during the first wave of the pandemic. Of these, 35.3% (88/249) required intensive care treatment; 16.5% (41/249) of them died due to the complications of COVID-19; 30.8% (64/208) of surviving patients could be followed up und were retrospectively analyzed at our center. The incidence of confirmed SSC-COVID was 7.8% (5/64). All SSC-COVID patients had an ICU stay >20 days, for invasive ventilation, positioning treatment, vasopressor treatment, but possible risk factors for SSC were not significant due to the small number of patients.
CONCLUSIONS: SSC-COVID is an emerging disease in post-COVID patients with a high incidence in our single-center cohort. SSC-COVID should be considered as a differential diagnosis, if unclear cholangiopathy or cholestasis persists after SARS-CoV-2 infection.
OBJECTIVE: The aim is to retrospectively analyze a cohort of hospitalized patients with first-wave (February 2020-June 2020) SARS-CoV-2 infection and persisting unclear cholangiopathy to determine the incidence of SSC-COVID and its risk factors.
RESULTS: A total of 249 patients were hospitalized at the university hospital in Tübingen, Germany, with SARS-CoV-2 infection during the first wave of the pandemic. Of these, 35.3% (88/249) required intensive care treatment; 16.5% (41/249) of them died due to the complications of COVID-19; 30.8% (64/208) of surviving patients could be followed up und were retrospectively analyzed at our center. The incidence of confirmed SSC-COVID was 7.8% (5/64). All SSC-COVID patients had an ICU stay >20 days, for invasive ventilation, positioning treatment, vasopressor treatment, but possible risk factors for SSC were not significant due to the small number of patients.
CONCLUSIONS: SSC-COVID is an emerging disease in post-COVID patients with a high incidence in our single-center cohort. SSC-COVID should be considered as a differential diagnosis, if unclear cholangiopathy or cholestasis persists after SARS-CoV-2 infection.
摘要：
背景：SARS-CoV-2感染和相关的COVID-19疾病可导致危重疾病，并有发生多器官衰竭的风险。随后，这可能会导致各种病理后遗症，如COVID-19存活后继发性硬化性胆管炎（SSC-COVID）。
目的：目的是回顾性分析第一波（2020年2月至2020年6月）SARS-CoV-2感染且持续不清楚的胆管病变的住院患者队列，以确定SSC-COVID的发生率及其危险因素。
结果：共有249名患者在蒂宾根大学医院住院，德国,在第一波大流行期间感染SARS-CoV-2。其中,35.3%(88/249)需要重症监护治疗；其中16.5%(41/249)因COVID-19并发症死亡；30.8%(64/208)的存活患者可在本中心进行回顾性分析。确诊SSC-COVID的发生率为7.8%(5/64)。所有SSC-COVID患者的ICU住院时间均>20天，用于有创通气，定位处理,加压药治疗,但由于患者数量少,SSC的可能危险因素并不显著.
结论：SSC-COVID是COVID后患者的一种新兴疾病，在我们的单中心队列中发病率很高。SSC-COVID应被视为鉴别诊断，如果SARS-CoV-2感染后仍存在不明确的胆管病变或胆汁淤积。
目的：目的是回顾性分析第一波（2020年2月至2020年6月）SARS-CoV-2感染且持续不清楚的胆管病变的住院患者队列，以确定SSC-COVID的发生率及其危险因素。
结果：共有249名患者在蒂宾根大学医院住院，德国,在第一波大流行期间感染SARS-CoV-2。其中,35.3%(88/249)需要重症监护治疗；其中16.5%(41/249)因COVID-19并发症死亡；30.8%(64/208)的存活患者可在本中心进行回顾性分析。确诊SSC-COVID的发生率为7.8%(5/64)。所有SSC-COVID患者的ICU住院时间均>20天，用于有创通气，定位处理,加压药治疗,但由于患者数量少,SSC的可能危险因素并不显著.
结论：SSC-COVID是COVID后患者的一种新兴疾病，在我们的单中心队列中发病率很高。SSC-COVID应被视为鉴别诊断，如果SARS-CoV-2感染后仍存在不明确的胆管病变或胆汁淤积。
